Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
TOYOTA GAZOO Racing and Ogier denied in dramatic finish
-
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences
-
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap
-
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
-
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Ann
-
Appointment of Director to Woodside Board
-
NOTICE OF THE TWENTY-FIFTH ANNUAL GENERAL MEETING OF SHAREHOLDERS
-
Fujitsu Japan and Juntendo University launch joint research for disaster-resilient, digital medical system
-
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
-
Flash News: OKX Launches 100% Fee Rebate Campaign
-
Supermicro Liquid-Cooled AI SuperClusters Will Power Large-Scale AI Data Center in Japan
-
LaVie Care Centers Takes Strategic Actions to Position the Company for Long-Term Success Amidst Challenging Skilled Nursing Operating Environment
-
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme
-
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a
-
SATO Technologies Corp. Reports Limited Incident at the Building Hosting Data Center One
-
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University
-
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis
-
TECNO exhibits its diverse smartphone and AIoT ecosystem with futuristic AR and AI products at COMPUTEX Taipei 2024, with the concept "Smart of Creation"
-
MSI Unveils New AI and Computing Platforms with 4th Gen AMD EPYC™ Processors at Computex 2024
-
Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
-
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
-
WEBTOON Entertainment Announces Public Filing of Registration Statement for Proposed Initial Public Offering
-
Mesoblast Corporate Presentation at Investor Conference
-
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
-
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
-
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
-
Fast Guard Service Shares Their Experience with Local Business Owner as the Best Security Guard Company in California
-
One in Five European Companies Are Facing Strong Pressure to Transform to Stay Viable
-
New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
-
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
-
FrogData Unveils Major AI Factory Upgrade to Revolutionize Automotive Retail Operations
-
izmostock Unveils Revolutionary Image Solution for Leasing Industry, Driving Unparalleled ROI and User Engagement
-
Summer Ready with Ulike Air 10: Your Smoothness Companion
-
When Solar PV Meets Blockchain: Pse.USDT Leading the Green Energy Revolution
-
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
-
GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
-
Miami Beach Inspires this Summer with Film, Fashion and Music Experiences
-
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated
-
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
-
Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Discovery of World War II fighter plane sets path for first U.S.-Papua New Guinea Sister City
-
Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
-
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
